Skip to main content

Table 4 Efficacy outcomes and preferences regarding IgG therapy at follow-up.

From: Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency

Efficacy outcomes

Number (%) of patients

Assessment of SCIG therapy by investigator

(N = 61)

   Excellent

54 (89)

   Acceptable

6 (10)

   Insufficient

1 (2)

Final assessment of therapy by investigator

(N = 61)

   Easy to learn and well feasible

50 (82)

   Learnable and feasible

9 (15)

   Too hard to learn as home therapy

2 (3)

Final assessment of therapy by patient

(N = 44)

   Gives more flexibility than IVIG

38 (86)

   Gives the same flexibility as IVIG

4 (9)

   Gives less flexibility than IVIG

2 (5)